Copyright Reports & Markets. All rights reserved.

Global Drug Contaminants Detection and Analysis Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Drug Contaminants Detection and Analysis by Type
    • 1.3.1 Overview: Global Drug Contaminants Detection and Analysis Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Drug Contaminants Detection and Analysis Consumption Value Market Share by Type in 2025
    • 1.3.3 Organic Pollutant Detection Products
    • 1.3.4 Inorganic Pollutant Detection Products
    • 1.3.5 Others
  • 1.4 Classification of Drug Contaminants Detection and Analysis by Detection Technology Principles
    • 1.4.1 Overview: Global Drug Contaminants Detection and Analysis Market Size by Detection Technology Principles: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Drug Contaminants Detection and Analysis Consumption Value Market Share by Detection Technology Principles in 2025
    • 1.4.3 Chromatography-Based Detection Products
    • 1.4.4 Mass Spectrometry-Based Detection Products
    • 1.4.5 Others
  • 1.5 Classification of Drug Contaminants Detection and Analysis by Drug Life Cycle Stages
    • 1.5.1 Overview: Global Drug Contaminants Detection and Analysis Market Size by Drug Life Cycle Stages: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Drug Contaminants Detection and Analysis Consumption Value Market Share by Drug Life Cycle Stages in 2025
    • 1.5.3 Early Process Risk Assessment and Screening
    • 1.5.4 Method Development and Methodology Validation
    • 1.5.5 Others
  • 1.6 Global Drug Contaminants Detection and Analysis Market by Application
    • 1.6.1 Overview: Global Drug Contaminants Detection and Analysis Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Chemical Pharmaceutical Industry
    • 1.6.3 Biopharmaceutical Industry
    • 1.6.4 Traditional Chinese Medicine and Natural Medicine Industry
    • 1.6.5 Others
  • 1.7 Global Drug Contaminants Detection and Analysis Market Size & Forecast
  • 1.8 Global Drug Contaminants Detection and Analysis Market Size and Forecast by Region
    • 1.8.1 Global Drug Contaminants Detection and Analysis Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Drug Contaminants Detection and Analysis Market Size by Region, (2021-2032)
    • 1.8.3 North America Drug Contaminants Detection and Analysis Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Drug Contaminants Detection and Analysis Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Drug Contaminants Detection and Analysis Market Size and Prospect (2021-2032)
    • 1.8.6 South America Drug Contaminants Detection and Analysis Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Drug Contaminants Detection and Analysis Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Eurofins Scientific (Luxembourg)
    • 2.1.1 Eurofins Scientific (Luxembourg) Details
    • 2.1.2 Eurofins Scientific (Luxembourg) Major Business
    • 2.1.3 Eurofins Scientific (Luxembourg) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.1.4 Eurofins Scientific (Luxembourg) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Eurofins Scientific (Luxembourg) Recent Developments and Future Plans
  • 2.2 SGS (Switzerland)
    • 2.2.1 SGS (Switzerland) Details
    • 2.2.2 SGS (Switzerland) Major Business
    • 2.2.3 SGS (Switzerland) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.2.4 SGS (Switzerland) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 SGS (Switzerland) Recent Developments and Future Plans
  • 2.3 Intertek (UK)
    • 2.3.1 Intertek (UK) Details
    • 2.3.2 Intertek (UK) Major Business
    • 2.3.3 Intertek (UK) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.3.4 Intertek (UK) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Intertek (UK) Recent Developments and Future Plans
  • 2.4 Thermo Fisher Scientific (USA)
    • 2.4.1 Thermo Fisher Scientific (USA) Details
    • 2.4.2 Thermo Fisher Scientific (USA) Major Business
    • 2.4.3 Thermo Fisher Scientific (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.4.4 Thermo Fisher Scientific (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Thermo Fisher Scientific (USA) Recent Developments and Future Plans
  • 2.5 Charles River Laboratories (USA)
    • 2.5.1 Charles River Laboratories (USA) Details
    • 2.5.2 Charles River Laboratories (USA) Major Business
    • 2.5.3 Charles River Laboratories (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.5.4 Charles River Laboratories (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Charles River Laboratories (USA) Recent Developments and Future Plans
  • 2.6 Labcorp Biopharma (USA)
    • 2.6.1 Labcorp Biopharma (USA) Details
    • 2.6.2 Labcorp Biopharma (USA) Major Business
    • 2.6.3 Labcorp Biopharma (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.6.4 Labcorp Biopharma (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Labcorp Biopharma (USA) Recent Developments and Future Plans
  • 2.7 WuXi STA / WuXi AppTec (China)
    • 2.7.1 WuXi STA / WuXi AppTec (China) Details
    • 2.7.2 WuXi STA / WuXi AppTec (China) Major Business
    • 2.7.3 WuXi STA / WuXi AppTec (China) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.7.4 WuXi STA / WuXi AppTec (China) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 WuXi STA / WuXi AppTec (China) Recent Developments and Future Plans
  • 2.8 Cambrex (USA)
    • 2.8.1 Cambrex (USA) Details
    • 2.8.2 Cambrex (USA) Major Business
    • 2.8.3 Cambrex (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.8.4 Cambrex (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Cambrex (USA) Recent Developments and Future Plans
  • 2.9 Pharmaron (China)
    • 2.9.1 Pharmaron (China) Details
    • 2.9.2 Pharmaron (China) Major Business
    • 2.9.3 Pharmaron (China) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.9.4 Pharmaron (China) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Pharmaron (China) Recent Developments and Future Plans
  • 2.10 Piramal Pharma Solutions (India)
    • 2.10.1 Piramal Pharma Solutions (India) Details
    • 2.10.2 Piramal Pharma Solutions (India) Major Business
    • 2.10.3 Piramal Pharma Solutions (India) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.10.4 Piramal Pharma Solutions (India) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Piramal Pharma Solutions (India) Recent Developments and Future Plans
  • 2.11 Syngene (India)
    • 2.11.1 Syngene (India) Details
    • 2.11.2 Syngene (India) Major Business
    • 2.11.3 Syngene (India) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.11.4 Syngene (India) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Syngene (India) Recent Developments and Future Plans
  • 2.12 Recipharm (Sweden)
    • 2.12.1 Recipharm (Sweden) Details
    • 2.12.2 Recipharm (Sweden) Major Business
    • 2.12.3 Recipharm (Sweden) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.12.4 Recipharm (Sweden) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Recipharm (Sweden) Recent Developments and Future Plans
  • 2.13 Almac Sciences (UK)
    • 2.13.1 Almac Sciences (UK) Details
    • 2.13.2 Almac Sciences (UK) Major Business
    • 2.13.3 Almac Sciences (UK) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.13.4 Almac Sciences (UK) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Almac Sciences (UK) Recent Developments and Future Plans
  • 2.14 MedPharm (UK)
    • 2.14.1 MedPharm (UK) Details
    • 2.14.2 MedPharm (UK) Major Business
    • 2.14.3 MedPharm (UK) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.14.4 MedPharm (UK) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 MedPharm (UK) Recent Developments and Future Plans
  • 2.15 CMIC (Japan)
    • 2.15.1 CMIC (Japan) Details
    • 2.15.2 CMIC (Japan) Major Business
    • 2.15.3 CMIC (Japan) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.15.4 CMIC (Japan) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 CMIC (Japan) Recent Developments and Future Plans
  • 2.16 Aenova (Germany)
    • 2.16.1 Aenova (Germany) Details
    • 2.16.2 Aenova (Germany) Major Business
    • 2.16.3 Aenova (Germany) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.16.4 Aenova (Germany) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Aenova (Germany) Recent Developments and Future Plans
  • 2.17 Sterling Pharma Solutions (UK)
    • 2.17.1 Sterling Pharma Solutions (UK) Details
    • 2.17.2 Sterling Pharma Solutions (UK) Major Business
    • 2.17.3 Sterling Pharma Solutions (UK) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.17.4 Sterling Pharma Solutions (UK) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Sterling Pharma Solutions (UK) Recent Developments and Future Plans
  • 2.18 Curia (USA)
    • 2.18.1 Curia (USA) Details
    • 2.18.2 Curia (USA) Major Business
    • 2.18.3 Curia (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.18.4 Curia (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Curia (USA) Recent Developments and Future Plans
  • 2.19 Ardena (Belgium)
    • 2.19.1 Ardena (Belgium) Details
    • 2.19.2 Ardena (Belgium) Major Business
    • 2.19.3 Ardena (Belgium) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.19.4 Ardena (Belgium) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Ardena (Belgium) Recent Developments and Future Plans
  • 2.20 Hovione (Portugal)
    • 2.20.1 Hovione (Portugal) Details
    • 2.20.2 Hovione (Portugal) Major Business
    • 2.20.3 Hovione (Portugal) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.20.4 Hovione (Portugal) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Hovione (Portugal) Recent Developments and Future Plans
  • 2.21 Delpharm (France)
    • 2.21.1 Delpharm (France) Details
    • 2.21.2 Delpharm (France) Major Business
    • 2.21.3 Delpharm (France) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.21.4 Delpharm (France) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.21.5 Delpharm (France) Recent Developments and Future Plans
  • 2.22 AGC Biologics (USA)
    • 2.22.1 AGC Biologics (USA) Details
    • 2.22.2 AGC Biologics (USA) Major Business
    • 2.22.3 AGC Biologics (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.22.4 AGC Biologics (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.22.5 AGC Biologics (USA) Recent Developments and Future Plans
  • 2.23 FUJIFILM Biotechnologies (Japan)
    • 2.23.1 FUJIFILM Biotechnologies (Japan) Details
    • 2.23.2 FUJIFILM Biotechnologies (Japan) Major Business
    • 2.23.3 FUJIFILM Biotechnologies (Japan) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.23.4 FUJIFILM Biotechnologies (Japan) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.23.5 FUJIFILM Biotechnologies (Japan) Recent Developments and Future Plans
  • 2.24 KBI Biopharma (USA)
    • 2.24.1 KBI Biopharma (USA) Details
    • 2.24.2 KBI Biopharma (USA) Major Business
    • 2.24.3 KBI Biopharma (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.24.4 KBI Biopharma (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.24.5 KBI Biopharma (USA) Recent Developments and Future Plans
  • 2.25 Rentschler Biopharma (Germany)
    • 2.25.1 Rentschler Biopharma (Germany) Details
    • 2.25.2 Rentschler Biopharma (Germany) Major Business
    • 2.25.3 Rentschler Biopharma (Germany) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.25.4 Rentschler Biopharma (Germany) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.25.5 Rentschler Biopharma (Germany) Recent Developments and Future Plans
  • 2.26 Ajinomoto Bio-Pharma Services (Japan)
    • 2.26.1 Ajinomoto Bio-Pharma Services (Japan) Details
    • 2.26.2 Ajinomoto Bio-Pharma Services (Japan) Major Business
    • 2.26.3 Ajinomoto Bio-Pharma Services (Japan) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.26.4 Ajinomoto Bio-Pharma Services (Japan) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.26.5 Ajinomoto Bio-Pharma Services (Japan) Recent Developments and Future Plans
  • 2.27 Bora Pharmaceuticals (Taiwan, China)
    • 2.27.1 Bora Pharmaceuticals (Taiwan, China) Details
    • 2.27.2 Bora Pharmaceuticals (Taiwan, China) Major Business
    • 2.27.3 Bora Pharmaceuticals (Taiwan, China) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.27.4 Bora Pharmaceuticals (Taiwan, China) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.27.5 Bora Pharmaceuticals (Taiwan, China) Recent Developments and Future Plans
  • 2.28 Kindeva (USA)
    • 2.28.1 Kindeva (USA) Details
    • 2.28.2 Kindeva (USA) Major Business
    • 2.28.3 Kindeva (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.28.4 Kindeva (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.28.5 Kindeva (USA) Recent Developments and Future Plans
  • 2.29 CordenPharma (Switzerland)
    • 2.29.1 CordenPharma (Switzerland) Details
    • 2.29.2 CordenPharma (Switzerland) Major Business
    • 2.29.3 CordenPharma (Switzerland) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.29.4 CordenPharma (Switzerland) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.29.5 CordenPharma (Switzerland) Recent Developments and Future Plans
  • 2.30 RSSL (UK)
    • 2.30.1 RSSL (UK) Details
    • 2.30.2 RSSL (UK) Major Business
    • 2.30.3 RSSL (UK) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.30.4 RSSL (UK) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.30.5 RSSL (UK) Recent Developments and Future Plans
  • 2.31 Tentamus (Germany)
    • 2.31.1 Tentamus (Germany) Details
    • 2.31.2 Tentamus (Germany) Major Business
    • 2.31.3 Tentamus (Germany) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.31.4 Tentamus (Germany) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.31.5 Tentamus (Germany) Recent Developments and Future Plans
  • 2.32 Element Materials Technology (UK)
    • 2.32.1 Element Materials Technology (UK) Details
    • 2.32.2 Element Materials Technology (UK) Major Business
    • 2.32.3 Element Materials Technology (UK) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.32.4 Element Materials Technology (UK) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.32.5 Element Materials Technology (UK) Recent Developments and Future Plans
  • 2.33 Nucro-Technics (Canada)
    • 2.33.1 Nucro-Technics (Canada) Details
    • 2.33.2 Nucro-Technics (Canada) Major Business
    • 2.33.3 Nucro-Technics (Canada) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.33.4 Nucro-Technics (Canada) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.33.5 Nucro-Technics (Canada) Recent Developments and Future Plans
  • 2.34 ALS (Australia)
    • 2.34.1 ALS (Australia) Details
    • 2.34.2 ALS (Australia) Major Business
    • 2.34.3 ALS (Australia) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.34.4 ALS (Australia) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.34.5 ALS (Australia) Recent Developments and Future Plans
  • 2.35 Aizant (India)
    • 2.35.1 Aizant (India) Details
    • 2.35.2 Aizant (India) Major Business
    • 2.35.3 Aizant (India) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.35.4 Aizant (India) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.35.5 Aizant (India) Recent Developments and Future Plans
  • 2.36 Wickham Laboratories (UK)
    • 2.36.1 Wickham Laboratories (UK) Details
    • 2.36.2 Wickham Laboratories (UK) Major Business
    • 2.36.3 Wickham Laboratories (UK) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.36.4 Wickham Laboratories (UK) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.36.5 Wickham Laboratories (UK) Recent Developments and Future Plans
  • 2.37 Toxikon (USA)
    • 2.37.1 Toxikon (USA) Details
    • 2.37.2 Toxikon (USA) Major Business
    • 2.37.3 Toxikon (USA) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.37.4 Toxikon (USA) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.37.5 Toxikon (USA) Recent Developments and Future Plans
  • 2.38 Evotec (Germany)
    • 2.38.1 Evotec (Germany) Details
    • 2.38.2 Evotec (Germany) Major Business
    • 2.38.3 Evotec (Germany) Drug Contaminants Detection and Analysis Product and Solutions
    • 2.38.4 Evotec (Germany) Drug Contaminants Detection and Analysis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.38.5 Evotec (Germany) Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Drug Contaminants Detection and Analysis Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Drug Contaminants Detection and Analysis by Company Revenue
    • 3.2.2 Top 3 Drug Contaminants Detection and Analysis Players Market Share in 2025
    • 3.2.3 Top 6 Drug Contaminants Detection and Analysis Players Market Share in 2025
  • 3.3 Drug Contaminants Detection and Analysis Market: Overall Company Footprint Analysis
    • 3.3.1 Drug Contaminants Detection and Analysis Market: Region Footprint
    • 3.3.2 Drug Contaminants Detection and Analysis Market: Company Product Type Footprint
    • 3.3.3 Drug Contaminants Detection and Analysis Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Drug Contaminants Detection and Analysis Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Drug Contaminants Detection and Analysis Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Drug Contaminants Detection and Analysis Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Drug Contaminants Detection and Analysis Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Drug Contaminants Detection and Analysis Consumption Value by Type (2021-2032)
  • 6.2 North America Drug Contaminants Detection and Analysis Market Size by Application (2021-2032)
  • 6.3 North America Drug Contaminants Detection and Analysis Market Size by Country
    • 6.3.1 North America Drug Contaminants Detection and Analysis Consumption Value by Country (2021-2032)
    • 6.3.2 United States Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Drug Contaminants Detection and Analysis Consumption Value by Type (2021-2032)
  • 7.2 Europe Drug Contaminants Detection and Analysis Consumption Value by Application (2021-2032)
  • 7.3 Europe Drug Contaminants Detection and Analysis Market Size by Country
    • 7.3.1 Europe Drug Contaminants Detection and Analysis Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 7.3.3 France Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Drug Contaminants Detection and Analysis Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Drug Contaminants Detection and Analysis Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Drug Contaminants Detection and Analysis Market Size by Region
    • 8.3.1 Asia-Pacific Drug Contaminants Detection and Analysis Consumption Value by Region (2021-2032)
    • 8.3.2 China Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 8.3.5 India Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Drug Contaminants Detection and Analysis Consumption Value by Type (2021-2032)
  • 9.2 South America Drug Contaminants Detection and Analysis Consumption Value by Application (2021-2032)
  • 9.3 South America Drug Contaminants Detection and Analysis Market Size by Country
    • 9.3.1 South America Drug Contaminants Detection and Analysis Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Drug Contaminants Detection and Analysis Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Drug Contaminants Detection and Analysis Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Drug Contaminants Detection and Analysis Market Size by Country
    • 10.3.1 Middle East & Africa Drug Contaminants Detection and Analysis Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Drug Contaminants Detection and Analysis Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Drug Contaminants Detection and Analysis Market Drivers
  • 11.2 Drug Contaminants Detection and Analysis Market Restraints
  • 11.3 Drug Contaminants Detection and Analysis Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Drug Contaminants Detection and Analysis Industry Chain
  • 12.2 Drug Contaminants Detection and Analysis Upstream Analysis
  • 12.3 Drug Contaminants Detection and Analysis Midstream Analysis
  • 12.4 Drug Contaminants Detection and Analysis Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Drug Contaminants Detection and Analysis market size was valued at US$ 9479 million in 2025 and is forecast to a readjusted size of US$ 15087 million by 2032 with a CAGR of 6.9% during review period.
    Drug Contaminants Detection and Analysis refers to a technical and service system that uses a series of analytical chemistry, microbiology and instrumental detection technologies to identify, quantify, trace and assess the risks of impurities, contaminants or unexpected substances in pharmaceuticals and related materials.
    Gross Profit Margin Level
    From a business model perspective, pharmaceutical contaminant detection and analysis falls into a high-value-added sector encompassing laboratory services, method development, compliance interpretation, and project management. For routine pharmacopoeia testing, release testing, and standard residual solvent/elemental impurity panels, the gross profit margin is typically moderate, generally between 35% and 45% based on industry experience. For nitrosamines, unknown impurity identification, E&L, particle traceability, and product-specific method development and validation, the gross profit margin often rises to 45%–60% due to the need for higher-level LC-MS/HRMS/ICP-MS platforms, experienced scientists, and more complex regulatory interpretation. For highly customized root cause investigations, toxicology threshold interpretation, and registration data support projects, the gross profit margin can potentially reach 55%–65%. Overall, the mainstream gross profit margin in the industry can be understood as 40%–55%. This assessment aligns with the publicly disclosed operating profit margins of large TIC/laboratory groups: Intertek's adjusted operating profit margin in 2025 was approximately 18.1%, and SGS's was approximately 15.5%. Since the gross profit margin of laboratory services is typically significantly higher than the operating profit margin, it's reasonable to conclude that this sector possesses a medium-to-high gross profit margin characteristic.
    Industry Drivers
    The strongest driver of this industry comes from the continuous upgrading of regulatory controls on trace contaminants. The FDA and EMA consistently require companies to conduct risk assessments, confirmatory testing, and control strategies regarding nitrosamines; ICH Q3D standardizes the elemental impurity control framework; and USP <1663>/<1664> makes extract/leachable analysis of pharmaceutical packaging materials, disposable systems, and contact materials a "must-have" for an increasing number of projects. As regulatory requirements evolve from "whether testing exists" to "whether there is sufficient sensitivity, traceability, and scientific interpretation," companies become more reliant on external specialized laboratories. The second driver comes from the increasing complexity of pharmaceuticals. The widespread use of sterile injectables, inhaled formulations, biologics, ADCs, cell and gene therapies, and single-use bioprocessing systems has made contaminant sources more dispersed and concealed. It's difficult for a single company's in-house laboratory to simultaneously possess HRMS, ICP-MS, microbiology, particle analysis, E&L, and toxicology interpretation capabilities. The third driving force is the increasing trend of outsourcing: expensive analytical platforms, time-consuming methodological validation, and rapidly changing regulations are leading more and more pharmaceutical companies to outsource the analysis of highly complex contaminants to service providers with global networks and specialized experience. Overall, this industry is upgrading from "supplementary testing services" to "critical infrastructure for pharmaceutical quality risk management."
    This report is a detailed and comprehensive analysis for global Drug Contaminants Detection and Analysis market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Drug Contaminants Detection and Analysis market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Drug Contaminants Detection and Analysis market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Drug Contaminants Detection and Analysis market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Drug Contaminants Detection and Analysis market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Drug Contaminants Detection and Analysis
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Drug Contaminants Detection and Analysis market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek (UK), Thermo Fisher Scientific (USA), Charles River Laboratories (USA), Labcorp Biopharma (USA), WuXi STA / WuXi AppTec (China), Cambrex (USA), Pharmaron (China), Piramal Pharma Solutions (India), etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Drug Contaminants Detection and Analysis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Organic Pollutant Detection Products
    Inorganic Pollutant Detection Products
    Others
    Market segment by Detection Technology Principles
    Chromatography-Based Detection Products
    Mass Spectrometry-Based Detection Products
    Others
    Market segment by Drug Life Cycle Stages
    Early Process Risk Assessment and Screening
    Method Development and Methodology Validation
    Others
    Market segment by Application
    Chemical Pharmaceutical Industry
    Biopharmaceutical Industry
    Traditional Chinese Medicine and Natural Medicine Industry
    Others
    Market segment by players, this report covers
    Eurofins Scientific (Luxembourg)
    SGS (Switzerland)
    Intertek (UK)
    Thermo Fisher Scientific (USA)
    Charles River Laboratories (USA)
    Labcorp Biopharma (USA)
    WuXi STA / WuXi AppTec (China)
    Cambrex (USA)
    Pharmaron (China)
    Piramal Pharma Solutions (India)
    Syngene (India)
    Recipharm (Sweden)
    Almac Sciences (UK)
    MedPharm (UK)
    CMIC (Japan)
    Aenova (Germany)
    Sterling Pharma Solutions (UK)
    Curia (USA)
    Ardena (Belgium)
    Hovione (Portugal)
    Delpharm (France)
    AGC Biologics (USA)
    FUJIFILM Biotechnologies (Japan)
    KBI Biopharma (USA)
    Rentschler Biopharma (Germany)
    Ajinomoto Bio-Pharma Services (Japan)
    Bora Pharmaceuticals (Taiwan, China)
    Kindeva (USA)
    CordenPharma (Switzerland)
    RSSL (UK)
    Tentamus (Germany)
    Element Materials Technology (UK)
    Nucro-Technics (Canada)
    ALS (Australia)
    Aizant (India)
    Wickham Laboratories (UK)
    Toxikon (USA)
    Evotec (Germany)
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Drug Contaminants Detection and Analysis product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Drug Contaminants Detection and Analysis, with revenue, gross margin, and global market share of Drug Contaminants Detection and Analysis from 2021 to 2026.
    Chapter 3, the Drug Contaminants Detection and Analysis competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Drug Contaminants Detection and Analysis market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Drug Contaminants Detection and Analysis.
    Chapter 13, to describe Drug Contaminants Detection and Analysis research findings and conclusion.

    Buy now